FitLife Brands, Inc. (FTLF) is a small-cap provider of nutritional supplements and wellness products, best known for brands such as MusclePharm and Irwin Naturals. Only two analysts currently publish price targets on the stock, which limits the statistical weight of any average. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The two verified targets are $17 from Roth Capital (analyst Sean McGowan, maintained Buy) and $18 from Lake Street Capital Markets (analyst Ryan Meyers, maintained Buy). The arithmetic mean is $17.50, producing a narrow low-to-high range of $17 to $18. Both firms rate the shares a Buy, with no Hold or Sell ratings in the current set.
Importantly, both targets predate the company's November 16, 2026 third-quarter report. Roth Capital had lowered its target from $25 to $17 after the prior quarter, and Lake Street had cut from $21 to $18 in April. Because the stock has since fallen sharply, the existing targets may not yet reflect the latest results and the recently amended credit agreement.
FitLife shares fell roughly 19% on November 16, closing near $6.83, after the company reported fiscal third-quarter revenue of $25.62 million (up 9% year over year but below estimates) and EPS that missed consensus. Adjusted EBITDA declined 13% to $3.3 million.
Reaching the $17.50 average analyst price target would require a gain of approximately 156% from current levels — a very large move that implies a full recovery to, and beyond, the levels the stock traded at earlier in 2026. Such a path would likely depend on a sustained turnaround in margins and legacy-brand sales rather than a single strong quarter.
Several factors could support a recovery. The acquired Irwin Naturals business generated $13.0 million in revenue during the quarter, up 91% from the prior-year partial period, with online sales and Amazon subscriber counts still growing. MusclePharm posted record online revenue during the quarter. Management also completed a restructuring expected to reduce annual operating expenses by about $1.2 million beginning in the fourth quarter, alongside additional supply-chain cost initiatives aimed at improving online margins.
The stock's low valuation — a single-digit forward P/E and a market capitalization of only about $65 million — means that even a modest operational improvement could translate into a sizable percentage move in the share price, given the small float. From what I see, this valuation setup is worth monitoring closely.
The obstacles are substantial. Legacy FitLife revenue fell 24% to $12.6 million, with online sales down 18% and wholesale revenue down 34% on reduced orders from certain retail partners, including GNC. The company cited a weak consumer environment, Amazon algorithm changes, and softness in specialty retail and health-food channels.
Balance-sheet pressure adds risk. The company ended the quarter with $39.3 million in debt against just $0.7 million in cash, and on October 30 it amended its credit agreement to raise the maximum funded-debt-to-EBITDA covenant ratio — a signal of tighter financial flexibility. With the stock near its 52-week low, investor confidence has deteriorated sharply.
Before the latest drop, the stock's 52-week range was approximately $7.66 to $19.23. The November selloff broke below that prior $7.66 low, with an intraday low near $6.28, meaning the former support level has now become potential resistance. The 52-week high of roughly $19 sits well above even the highest analyst target, underscoring how far the shares have fallen. The $7.50–$8.00 zone may act as an initial hurdle, while round-number levels near $10 and $12 could serve as longer-term reference points on any recovery path.
Analyst price targets generally reflect a roughly 12-month research horizon, though neither firm has published a precise stated timeframe for these targets. Because the targets were issued before the latest earnings report, investors should watch closely for any revisions following the miss.
Key items to monitor include fourth-quarter and full-year results, evidence that the $1.2 million cost-savings program is translating into improved margins, Irwin and MusclePharm online momentum, legacy wholesale and online stabilization, debt reduction and covenant compliance, and any broader shifts in consumer spending on discretionary wellness products. I’m watching this closely for signs of stabilization.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly traded name like FTLF, these signals can help traders spot shifts in momentum and trend more efficiently than manual scanning alone. In my view, this kind of automated support adds useful context when evaluating names with limited analyst coverage.
The $17.50 central target is the simple average of two Buy-rated analyst price targets, not a published consensus figure, and it reflects a view formed before the company's latest earnings miss and covenant amendment. At roughly $6.83, the stock would need to climb about 156% to reach that level — a very large move requiring a credible, sustained recovery in margins and legacy-brand sales rather than a single good quarter. The narrow $17-to-$18 analyst range signals broad agreement among the small group of covering firms, but the dated nature of those targets means they carry less weight than they would after a fresh review. The most important near-term signals will be margin improvement from the cost program, stabilization in legacy revenue, debt reduction, and any analyst revisions that follow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FTLF saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 78 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 48 cases where FTLF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for FTLF turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTLF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for FTLF entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for FTLF's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +3.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTLF advanced for three days, in 140 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
FTLF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.580) is normal, around the industry mean (6.914). P/E Ratio (11.896) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.922) is also within normal values, averaging (5.003).
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. FTLF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry FoodMajorDiversified